Department of Radiation Oncology, Zuoying Armed Forces General Hospital, Kaohsiung, Taiwan.
Gynecol Oncol. 2012 Oct;127(1):186-90. doi: 10.1016/j.ygyno.2012.06.010. Epub 2012 Jun 12.
The purpose of this study was to explore the possible association between coronary artery disease (CAD) risk and cervical cancer.
We used data from the National Health Insurance system of Taiwan to address the research topic. The exposure cohort contained 728 patients with cervical cancer. Each cancer patient was randomly frequency-matched with 4 participants by age, index-month, and index-year from the general population who did not have a cancer history before the index date (control group). Cox's proportion hazard regression analyses were conducted to estimate the relationship between cervical cancer and CAD risk.
Among patients with cervical cancer, the overall risk for developing CADs was significantly lower than that of the control group [adjusted hazard ratio (aHR): 0.57, 95% confidence interval (95% CI): 0.41-0.79]. Further analyses revealed that the lower risk was observed only in patients with older age (aHR: 0.57, 95% CI: 0.40-0.82), a shorter follow-up duration (aHR: 0.47, 95% CI: 0.31-0.72), or with estrogen supplements (aHR: 0.39, 95% CI: 0.22-0.68).
The findings from this population-based study suggest that estrogen supplements are associated with a decreased CAD risk in patients with cervical cancer.
本研究旨在探讨冠状动脉疾病（CAD）风险与宫颈癌之间可能存在的关联。
我们使用了来自台湾全民健康保险系统的数据来研究这个课题。暴露队列包含了 728 名宫颈癌患者。每个癌症患者均按照年龄、索引月份和索引年份，与来自一般人群且在索引日期之前无癌症史的 4 名参与者进行频率匹配（对照组）。采用 Cox 比例风险回归分析来估计宫颈癌与 CAD 风险之间的关系。
在宫颈癌患者中，总体发生 CAD 的风险明显低于对照组[调整后的危险比（aHR）：0.57，95%置信区间（95% CI）：0.41-0.79]。进一步分析表明，仅在年龄较大（aHR：0.57，95% CI：0.40-0.82）、随访时间较短（aHR：0.47，95% CI：0.31-0.72）或使用雌激素补充剂（aHR：0.39，95% CI：0.22-0.68）的患者中观察到这种较低的风险。
这项基于人群的研究结果表明，雌激素补充剂与宫颈癌患者 CAD 风险降低有关。
